FTSE 100 Closes Higher as Vodafone Surges 13% and easyJet Jumps on Apollo Bid 📈 The FTSE 100 ended higher on Friday in calmer trading, helped by a double-digit rise
Great Request Show: Zak Mir looks at technical outlook for AVCT, EZJ, FMET, FCM, PALM & QHE
Zak Mir takes a charting look at some of the latest requested stocks, including Avacta, easyJet, Fulcrum Metals, First Class, Panther Metals, and Quantum Helium.
Avacta cuts convertible bond debt with £3.67m payment
Accelerated Amortized Payment of Convertible Bond Installment
RNS Hotlist with Zak Mir: UJO, QBT, ZEN, REV, PLSR, HAMA, SVML, FMET, PYC, EDX, INT, TUN, APTA, GMET, CGO, VCP & AVCT
Union Jack Oil plc (UJO), acknowledges the receipt of a requisition notice dated 7 July 2026 from shareholders who hold 20,650,096 ordinary shares in the Company representing 14.09% of the total voting
Avacta Appoints Patrick Vink as Deputy Chairman
Avacta Therapeutics (AIM: AVCT) has appointed healthcare executive Dr Patrick Vink to its board as non-executive deputy chairman and senior independent director.
Share Talk Weekly Stock Market News Review, Sunday 28th June 2026
London’s leading stock indices ended the week on a subdued note, with the FTSE 100 edging lower after briefly trading near a two-month high. The blue-chip index closed down 21.87
RNS Hotlist with Zak Mir: QHE, AVCT, MPL, CASP, IMM, BVC, APTA, EZJ, ORCP, TRP & ZIN
Quantum Helium Limited (QHE) provided shareholders with a review of the key milestones achieved over the past twelve months ahead of the Company’s Extraordinary General Meeting (“EGM”), which is scheduled to
Avacta advances AVA6000 towards pivotal US trial
Avacta Therapeutics (AIM: AVCT) has secured a significant regulatory milestone after reaching an agreement with the US Food and Drug Administration on the pivotal trial design for its lead cancer
Shareholders give overwhelming support to Avacta proposals
Avacta Group PLC announced that all resolutions were passed at its Annual General Meeting, with overwhelming shareholder support for each proposal.
Avacta Extends Cash Runway as Clinical Pipeline Advances
Avacta Therapeutics (AIM: AVCT) has reported strong progress across its oncology pipeline in the first half of 2026, highlighting advances in both its clinical programmes and balance sheet ahead of
Share Talk Weekly Stock Market News Review, Sunday 7th June 2026
London markets ended the week on a mixed note as gains in the FTSE 100 were offset by weakness in mining shares, while stronger-than-expected US jobs data triggered a sell-off
RNS Hotlist with Zak Mir: AVCT, IBAI, ALRT, KEN, BMV, RPI, IOF, FORG & CTL
Avacta Therapeutics (AVCT), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, announced that it has raised gross proceeds of approximately £9 million from institutional investors and existing